Safety and tolerability of Nilotinib in patients with Huntington’s disease
Objective: To investigate the safety and tolerability of nilotinib, an FDA-approved drug for leukemia, in individuals with Huntington’s disease (HD). Background: Previous clinical studies in…Comorbid neuropathological features in multiple system atrophy
Objective: To elucidate the distribution of comorbid neuropathology in multiple system atrophy (MSA) and its clinical correlation. Background: Multiple protein accumulations are often present in…Administration of the mGlu2 positive allosteric modulator BINA as monotherapy improves parkinsonism in the MPTP-lesioned marmoset
Objective: To assess the effect of selective metabotropic glutamate type 2 (mGlu2) receptor activation on parkinsonism as monotherapy in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmoset compared to…Prevalence of sleep disorders in Parkinson’s disease patients at a Brazilian movement disorders center in 2022
Objective: To describe the prevalence of the main sleep disorders in patients with Parkinson's disease at a referral outpatient clinic for movement disorders. Background: Parkinson's…A Man Who Has Been Presenting with Pruritus and Myoclonus
Objective: While various neurological symptoms of sparganosis including have been reported, this is the first documented instance in which sparganosis presented with myoclonus. Background: Sparganosis…DaTscan striatal binding ratio dynamics in mutations carriers at risk for Parkinson’s disease: A 2-year prospective study
Objective: To investigate the temporal dynamics of striatal binding ratios (SBRs) among individuals with Parkinson's disease (PD)-related mutations and its' association with likelihood ratio (LR)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.